Kornimate/medical-research-clean huggingface dataset:
precision nudging for hypertension management: observational study

Conditions: Hypertension

Summary: the purpose of the proposed observational study is to explore the relations between data-driven personalization and equitable health outcomes in a digital health intervention (dhi) for hypertension management. in the current intervention, behavioral reinforcement learning is applied to personalize intervention content to maximize the behavioral outcomes of three target behaviors critical for effective hypertension management: clinical encounters, medication adherence, and self-monitoring of blood pressure (smbp).


Eligibility criteria:
inclusion criteria: * patient of cone health. * hypertension condition considered "uncontrolled" (signaled by an eligibility indicator). * most recent blood pressure reading is at or higher than 160/90. exclusion criteria: * non-english speaking. * globally unsubscribed. * locally unsubscribed. * deceased.

Keywords: medication adherence self-monitoring of blood pressure clinical encounters health equity precision nudging digital health intervention behavioral reinforcement learning
effectiveness of graded motor imagery to prevent crps in patients with distal radius fracture after surgery

Conditions: Wrist Fracture; CRPS (Complex Regional Pain Syndromes); Distal Radius Fracture; Surgery

Summary: the study would like show that patients who follow a protocol with gmi are less probability to develop crps

distal radius fractures (drf) has a high frequency in adults. studies show that the upper limb is frequently affected by crps, especially if is preceded by a fracture. recent studies suggest that changes in cortical structures can contribute to the onset of crps. gmi is a approved and efficacy method in crps rehabilitation, because it trains modified cortical areas throught 3 stadies: left-right discrimination, visual motor imagery and mirror therapy. literature shows that there are any studies about gmi efficacy on prevention crps in drf after surgery. this study would like to demostrate that, appling gmi in the early stages of rehabilitation plus standard rehabilitation protocol of drf after surgery, crps cases are reducted.

Eligibility criteria:
inclusion criteria: * patients with distal radius fracture after surgery * 18 to 75 years old * male and female exclusion criteria: * uncompliants patients * patients with neurological disorders or cognitive impairment * patients with tfcc injury or both ulna and radius fractures * patients with visually impairment * patients who don't speak or understand oral and written italian language

Keywords: gmi crps distal radius fracture
prospective evaluation of drug-eluting stents in routine clinical practice (asan pci registry)

Conditions: Coronary Artery Disease

Summary: the objective of this study is to evaluate effectiveness and safety of drug-eluting stent implantation in the "real world" daily practice.


Eligibility criteria:
inclusion criteria: * coronary disease amenable to percutaneous coronary intervention (pci) * no clinical and lesion limitations exclusion criteria: * patients with a mixture of several drug eluting stents * terminal illness with life expectancy less than 1 year * patients with cardiogenic shock

Keywords: coronary artery disease drug eluting stent
evaluation of ultrasensitive chromosomal aneuploidy detection for detecting minimal residual disease in multiple myeloma

Conditions: Multiple Myeloma

Summary: despite the significantly higher complete remission rates and improved survival achieved over the last decade，multiple myeloma (mm) patients continue to relapse due to persistence of minimal residual disease (mrd). currently, numerous studies have evaluated the prognostic value of mrd by detecting immunophenotypic and immunoglobulin (ig) gene rearrangements from bone marrow aspiration samples. here the investigators intend to study the clinical utility of ultrasensitive chromosomal aneuploidy detection (ucad) as an mrd assay, which is based on plasma cell-free dna(cfdna) low-coverage whole-genome sequencing. ucad is non-invasive and applicable for tumors with high heterogeneity and extramedullary invasions.

in multiple myeloma, minimal residual disease (mrd) refers to myeloma cells that are present in the bone marrow after a clinical response has been measured and the patient is in remission. a patient who tests "mrd negative" after treatment for myeloma has less than one myeloma cell per million bone marrow cells. data from recent clinical trials suggest that patients with such a low level of disease may be less likely to experience a relapse of their condition than patients with higher levels. in recent years, mrd testing is now be applied in the management of patients receiving standard therapies for the disease. chromosomal instability(cin) results from errors in chromosome segregation during mitosis, leading to structural and numerical chromosomal abnormalities. it will generate genomic heterogeneity that acts as a substrate for natural selection. furthermore, it is proved that tumors with aneuploidies and polyploidy resulting from whole-genome doubling are related with metastasis, treatment resistance, and decreased overall survival. it is estimated that 60%-80% of human tumors exhibit chromosomal abnormalities suggestive of cin. cin positively correlates with tumor stage and is enriched in relapsed as well as metastatic tumor specimens. due to the ubiquity of cin in cancer cells and cancer cell releasing dna into peripheral blood (pb) when apoptosis, it is a potentially non-invasive way to detect cin in pb cfdna from the mm patients to character mrd level. ucad is a new method to detecting cin in the dna sample from patients, including extracting cfdna from pb, analyzing dna by low-coverage whole-genome sequencing, processing the data by bio-information techniques, and finally optimizing the management of mm patients.

Eligibility criteria:
inclusion criteria: * patients new diagnosed with mm and with the curative effect at least vgpr. * male or female patients aged \>= 18 years. * participants signed informed consent form. exclusion criteria: * age under 18 years * individuals unwilling to sign the consent form or unwilling to provide pb for test or unwilling to provide the medical record. * individuals unwilling to participate in this trial.

Keywords: multiple myeloma minimal residual disease chromosomal aneuploidy detection chromosomal instability
post-approval study of the guidant carotid stent systems and embolic protection systems: capture

Conditions: Atherosclerotic Disease, Carotid

Summary: this purpose of this study is to collect data on the fda-approved acculink(tm) carotid stent system and fda 510(k)-cleared accunet(tm) embolic protection system for the treatment of patients with atherosclerotic disease, when used by physicians under commercial use conditions.

capture is a post-approval study to collect information on the safety and effectiveness of the acculink and accunet since the approval/clearance of these devices by the fda. the acculink stent is an elastic-like metal tube that is used to hold open a narrow part of a blood vessel. the accunet is a wire mesh basket that is placed in the vessel to catch material (blood clots, fatty material) that could break off from the narrowed area of the blood vessel and block blood flow downstream during the stent procedure. another goal of the capture study is to confirm that the acculink and accunet can be used safely by physicians with varying levels of experience in stenting procedures. the basis for fda's approval/clearance of the acculink and accunet was the archer trials (acculink/accunet for revascularization of carotids in high-risk patients). the archer trials were conducted to collect data on the safety and effectiveness of the acculink and accunet when used in the treatment of carotid artery disease in patients at high risk for surgical treatment (carotid endarterectomy) because of medical or surgical comorbidities. the archer trials showed that the acculink, used with or without the accunet, is a safe and effective treatment option based on the rate of death, stroke, and myocardial infarction at 30 days, and stroke at one year.

Eligibility criteria:
inclusion criteria: * patient's physician used an acculink and/or accunet

Keywords: atherosclerotic disease
the insyte (management of parkinson's disease psychosis in actual practice) study

Conditions: Parkinson Disease Psychosis

Summary: to examine the current disease progression of pdp, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers


Eligibility criteria:
inclusion criteria: 1. adult males and females ≥ 18 with pdp 2. ability to understand and read english 3. patient is willing and able to sign an informed consent form (icf), or have a legally authorized representative willing and able to consent on the patient's behalf 4. possess the symptoms commonly associated with pdp, e.g., hallucinations and delusions that cannot be reasonably attributed to other causes exclusion criteria: 1. patient is unwilling to participate in the non-interventional study 2. patient is currently participating in or is planning to participate in an investigational clinical trial
a study of pertuzumab in participants with metastatic breast cancer

Conditions: Breast Cancer

Summary: this study will evaluate the efficacy and safety of pertuzumab (rhumab 2c4) in participants with metastatic breast cancer which has progressed during or after standard chemotherapy and which is not amenable to curative therapy. those who are maintaining a response to therapy or who have stable disease at the end of the formal study period will continue treatment until disease progression or unacceptable toxicity. approximately 120 participants will be enrolled.


Eligibility criteria:
inclusion criteria: * females at least 18 years of age * histologically-confirmed metastatic breast cancer with low her2 expression and at least one measurable lesion according to response evaluation criteria in solid tumors (recist) * karnofsky performance status at least 80% * disease progression on/after up to 2 different chemotherapy regimens, including an anthracycline-containing therapy * left ventricular ejection fraction (lvef) at least 50% * adequate liver function exclusion criteria: * pleural effusions, ascites, or bone lesions as the only manifestation(s) of cancer * pulmonary or central nervous system (cns) metastases * chemotherapy, radiotherapy, or immunotherapy within 4 weeks; or hormone therapy within 2 weeks of day 1 * previous treatment with any drug that targets the her2 receptor family * previous treatment with corticosteroids as cancer therapy * history of significant cardiac disease * major surgery or trauma within 4 weeks of day 1 * pregnant or lactating women
prediction of incidence of liver cancer by use of real-time tissue elastography

Conditions: Chronic Hepatitis B; Chronic Hepatitis C

Summary: this is a multi-center cohort study in which the real-time tissue elastography® measurements will predict prospectively the incidence of hepatocellular carcinoma, the incidence and severity of gastroesophageal varices ascites and decompensated cirrhosis in hepatitis b or c patients.

the aim of this study is to validate the predictive value of real-time tissue elastography® by comparison with serum marker or fibroscan® in chronic hepatitis b or c patients. every year and for three years, we performed real-time tissue elastography®, blood sampling, gastrointestinal endoscopy. if in the hospital they can perform fibroscan®, fobroscan® also be performed. subjects were also performed ultrasonography (us), computed sonography (ct) or magnetic resonance imaging (mri) evry four or six months. the time between the real-time tissue elastography®, blood sampling, gastrointestinal endoscopy and firoscan® must not exceed four weeks.

Eligibility criteria:
inclusion criteria: * male or female and at least 20 years of age * chronic hepatitis b or chronic hepatitis c exclusion criteria: * evidence or history of hepatocellular carcinoma * history of alcohol abuse (alcohol intake \> 20g/day) * pregnant or lactating patients * psychosis

Keywords: hepatitis b virus hepatitis c virus chronic hepatitis liver chlorosis liver stiffness liver fibrosis
examining the effects of diet on health with an online program

Conditions: Type 2 Diabetes

Summary: the study is a pilot, designed to provide data regarding the feasibility and acceptability of conducting such a study on a larger scale. the present study is a randomized controlled clinical trial comparing two programs to help people manage diabetes and lose weight, one using a moderate-carbohydrate diet promoted by the american diabetes association (ada) and the other using on a low-carbohydrate diet (lc) and mindfulness and positive affect lifestyle modifications. intervention content will include information about nutrition (american diabetes association recommended diet or carbohydrate restriction) and, in the lc group, emotion regulation, positive affect, and mindful eating strategies.

approximately individuals with type 2 diabetes will be randomized in a 1:1 ratio to treatment groups. classes will occur online. participants will be evaluated at 0, 16, and 32 weeks. our main outcome of interest is hba1c (glycated hemoglobin, a measure indicative of blood glucose levels and tied to diabetes severity).

Eligibility criteria:
inclusion criteria: 1. hba1c 6.5%-9% at screening. 2. aged 18 years old and older 3. bmi 25 and above. 4. willing and able to participate in the interventions such as having sufficient control over their food intake. must have the ability to make choices about the food they eat; cannot have a lifestyle in which they eat out most of their meals.) exclusion criteria: 1. unable to provide informed consent. 2. non english speaker. 3. no current use of insulin, no immediate plans to start or increase diabetic mediations, and no use of diabetes medications besides metformin. 4. a substance abuse, mental health, or medical condition that, in the opinion of investigators, will make it difficult for the potential participant to participate in the intervention. such conditions may include: cancer, liver failure, unstable coronary artery disease, severe emphysema, binge eating disorder or history of binge eating disorder, bulimia or strong history of bulimia. 5. previous use or recent changes in medications that can interfere with the measures used in the study: current use of insulin; use of systemic (oral or iv) corticosteroids in the 6 months prior to enrollment or severe autoimmune disorders or other conditions (e.g. rheumatoid arthritis, lupus), that are likely to require these medications; and initiation of new class of psychiatric medications in past 2 months. 6. pregnant or planning to get pregnant in the next 12 months, breastfeeding or less than 6 months post-partum. 7. current use of weight loss medications or supplements such as alli or amphetamine-based drugs that are believed to have some effect on weight. 8. history of or planned weight loss surgery. 9. vegan or vegetarian. the intervention diets are more challenging for vegan and vegetarian participants. 10. no or very limited internet access at a computer. must be able to complete the online assessments and access the online class materials.

Keywords: diabetes obesity mindful eating positive affect low carbohydrate ketogenic diet
correlation of solitary dilated duct at mammography with ultrasonography and anatomopathological findings

Conditions: Mammary Duct Ectasia of Unspecified Breast; Mammographic Findings; Female

Summary: mammograms performed at the diagnostic imaging department of the "instituto brasileiro de controle do câncer" (ibcc - brazilian cancer control institute) will be prospectively evaluated. patients who present a solitary dilated duct visualized by mammography will be submitted to breast ultrasonography. in case of detection of lesion, a percutaneous biopsy will be performed.

purpose: to determinate the incidence, pathological significance and risk factors associated with the presence of solitary dilated duct visualized at mammography exam. methods: mammograms performed at the diagnostic imaging department of the "instituto brasileiro de controle do câncer" (ibcc - brazilian cancer control institute) will be prospectively evaluated. patients who present a solitary dilated duct visualized by mammography will be included in the study. these patients will be recalled in order to be submitted to an ultrasonography directed to the mammographic finding. patients who present lesions on ultrasonography will undergo method-guided percutaneous biopsy. patients with ductal ectasia, without evident lesions, will be followed for 2 years to evaluate stability by means of mammography or ultrasonography every 6-month intervals.

Eligibility criteria:
inclusion criteria: * identification of a solitary dilated breast duct at mammography exclusion criteria: * previous breast surgery at same side of detection of dilated duct

Keywords: mammography ductal ectasia breast neoplasm/diagnostic imaging mammary glands, human/pathology female
study on the effect and mechanism of lupatadine fumarate in the treatment of allergic rhinitis

Conditions: Allergic Rhinitis

Summary: in china, the prevalence of allergic rhinitis reaches 17.6% and is increasing year by year, seriously affecting the quality of life of patients. some patients still cannot be effectively treated. so it is urgent to study the pathogenesis of ar and find new therapeutic targets. lupatadine fumarate has the dual effects of antihistamine and platelet-activating factor (paf), and it is the only potent and highly effective allergy drug with both antihistamine and paf antagonism currently on the marke. the exact mechanism of lupatadine fumarate in relieving nasal congestion in patients with ar is unknown. tight junction proteins (tjs) play an important role in maintaining endothelial barrier function, and tj disruption disrupts barrier function and promotes inflammation. 15-lox(15-lipoxygenase) disrupts tight junctions at the blood-brain barrier. it increases cerebral vascular permeability and contributes to cerebral edema. in a mouse model of atherosclerosis, 15(s)-hete, the major metabolite of 15-lox, enhances the phosphorylation of zo-2 at the thr-1/1 residue through mek1-erk770/772 activation, leading to the dissociation of zo-1 from occludin and disrupting the endothelial tj and its barrier function. so we want to study the effects and mechanisms of lupatadine fumarate in the treatment of allergic rhinitis (ar) and whether lupatadine fumarate is directly related to 15-lo1.


Eligibility criteria:
inclusion criteria: * adult patients (18-65 years). * patients with allergic rhinitis were diagnosed based on clinical history and positive dust mite sensitization tests (skin prick test and/or specific ige). exclusion criteria: * received glucocorticoids, immunomodulatory, antihistamine drugs, and other medications that may affect the study results within the last 1 month. * nasal diseases such as upper respiratory tract infections, chronic sinusitis with or without nasal polyps, and nasal sinus tumors. * history of nasal sinus surgery. * with other immune and allergic diseases. * patients with a combination of severe cardiac, cerebrovascular or pulmonary - diseases, aspirin triad, primary ciliary dyskinesia, immune deficiency, and coagulation disorders. * pregnant women. * smokers.
establishment of a prospective clinical-biological database

Conditions: Sarcoma

Summary: a clinical and biological database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. this database is specific to sarcoma

liposarcomas (lps) are soft tissue tumours of mesenchymal origin. the most common histological subtypes, represented by well differenciated lipsarcomas (wd-lps) and dedifferenciated (dd-lps), are characterized by the quasi-systematic amplification of the q13-15 of chromosome 12 containing the mdm2 gene. the systematic amplification of the mdm2 gene is such that it is used clinically to distinguish wd/dd-lps from other types of sarcomas. these observations raise key questions about the high selection pressure that leads to the almost systematic amplification of mdm2 during the development of these lps. mdm2 is an oncoprotein whose roles in p53 tumour suppressor degradation are broadly described. however, the different inhibitors targeting this interaction were disappointing in clinical trials. recently a team from the u1194 inserm unit of the ircm which collaborates in this project showed by a pan-genomics analysis, that mdm2 is recruited to chromatin within a multiproteic complex having as target a transcriptional program involved in the metabolism and in particular in the biosynthesis of the serin. this clinical-biological basis will allow the continuation of this research project on liposarcomas and the development of new research projects on other histological types of sarcomas.

Eligibility criteria:
inclusion criteria: * men or women \> 18 years * patient treated by surgery for : a primitive sarcoma and/or local relapse sarcoma and/or metastatic localisation of sarcoma * patient accepted blood sample * patient treated by radiotherapy before or after the surgery * patient signed informed consent exclusion criteria: * patient not affiliated to french social protection system * patient under guardianship * patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons * pregnancy and/or feeding * patient take care in an emergency situation

Keywords: biological specimen banks radiotherapy
residential cleaning of indoor air to protect copd patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study looks at whether air cleaning devices put in the bedroom and living room of your home could reduce the irritation of your lungs and body that is caused by indoor air pollution. while participating in this study there will be two, 2 month long study segments (study period 1 and study period 2) where the air filter units, placed in your living room and bedroom windows, will be turned on at your home.


Eligibility criteria:
inclusion criteria: * severe copd (fev1 \< 50%) * live in monroe county * referred for pulmonary rehabilitation * suffered from an aecopd in the past year * have standard sized windows in their bedroom and living room amenable to installation of the hepairx® device * expect to sleep each night of the 4 months (2 months of period 1, and 2 months of period 2) in either their bedroom or living room for at least 6 hours/night, and not use other air filtering devices during the study exclusion criteria: * under age 18 * smoking at the time of their prior copd exacerbation * current smokers * those who live with an active smoker * those with an occupation that has a high pollutant exposure (e.g. professional drivers) * those who already have a home air filtration device (other than basic furnace filter)